Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

Video

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses future research with CAR T-cell therapy in hematologic malignancies.

​In the B-cell lymphoma space, lisocabtagene maraleucel ​(liso-cel) appears to be associated with low rates of severe CAR T-cell therapy–related toxicities, ​Hill says.

Additionally, future research efforts should compare the efficacy and safety profiles of tisagenlecleucel (Kymriah), ​liso-cel, and axicabtagene ciloleucel (Yescarta), ​explains Hill. Further investigation may also shed light on subtle differences in the makeup of each product.

Ultimately, sorting out the unique characteristics ​of the 3 products will help the field identify which patients will benefit most from each ​therapy, Hill concludes.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
© 2024 MJH Life Sciences

All rights reserved.